Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of chemoimmunotherapy with or without metformin in first-line treatment of squamous cell lung carcinoma with high FDG uptake
KCT0008659Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of metformin in Pulmonary squamous cell carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Oct 2023; status: recruiting.
02
Drugs
metformin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on KCT0008659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008659.